Related Experiment Video
Updated: May 12, 2026

Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR
Published on: December 6, 2014
Therapeutic management of primary immunodeficiency in older patients
Nisha Verma1, Anthony Thaventhiran, Benjamin Gathmann
1Department of Immunology and Molecular Pathology, Royal Free Hospital and University College London, London, UK.
Insights
Primary immunodeficiency disease (PID) increasingly affects elderly patients, yet clinical evidence for their management is scarce. This review focuses on antibody deficiency syndromes, the most common PID type in older adults.
Area of Science:
- Immunology
- Geriatrics
- Clinical Medicine
Background:
- Primary immunodeficiency disease (PID) traditionally diagnosed in children.
- Advances in diagnosis and treatment increase the number of elderly PID patients.
- Limited research exists for managing PID in older adults.
Purpose of the Study:
- To review the management of PID in the elderly.
- To focus on antibody deficiency syndromes, prevalent in this demographic.
Main Methods:
- Review of existing literature and data from the European Society for Immunodeficiencies.
- Analysis of management strategies for elderly PID patients.
- Focus on predominantly antibody deficiency syndromes.
Main Results:
- Elderly PID patients are increasingly common.
- Predominantly antibody deficiency syndromes are the most frequent PID type in the elderly.
- Clinical management often relies on extrapolations from other patient groups.
Conclusions:
- There is a critical need for evidence-based guidelines for elderly PID management.
- Further research is required to optimize care for this growing patient population.
- Antibody deficiency syndromes require specific attention in geriatric PID care.
Abstract:
Primary immunodeficiency disease (PID) has traditionally been viewed as a group of illnesses seen in the paediatric age group. New advances in diagnosis and treatment have led to an increase in the number of elderly PID patients. However, there is lack of research evidence on which to base clinical management in this group of patients. Management decisions often have to be based therefore on extrapolations from other patient cohorts or from younger patients. Data from the European Society for Immunodeficiencies demonstrates that the vast majority of elderly patients suffer from predominantly antibody deficiency syndromes. We review the management of PID disease in the elderly, with a focus on antibody deficiency disease.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cell-mediated Immune Responses
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

